Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Jnit: NT\$ thousand Accounting Title	2016/03/31	2015/12/31	2015/03/31
<u> </u>	2010/03/31	2015/12/31	2015/03/31
Balance Sheet			
Current assets			
Total cash and cash equivalents	458,006	305,619	1,176,33
Total Current investments in debt instrument without active market	610,826	859,867	150,00
Notes receivable due from related parties, net	0	71	(
Accounts receivable, net	5,575	18,570	10,52
Accounts receivable due from related parties, net	30	0	6
Other receivables, net	12,380	2,892	8,93
Other receivables due from related parties, net	0	0	
Total current tax assets	4,212	4,038	3,18
Total inventories	24,433	22,627	18,56
Total prepayments	33,833	21,576	12,11
Total other current assets	10,031	9,323	1,41
Total current assets	1,159,326	1,244,583	1,381,13
Non-current assets			
Total Non-current investments in debt instrument without active market	30,000	30,000	30,00
Total property, plant and equipment	216,570	199,876	188,10
Total intangible assets	368	580	1,51
Deferred tax assets	39,672	40,173	40,13
Total other non-current assets	16,019	3,174	8,73
Total non-current assets	302,629	273,803	268,498
Total assets	1,461,955	1,518,386	1,649,63
Current liabilities			
Total notes payable	0	0	
Total accounts payable	17,785	19,619	7,33
Total accounts payable to related parties	0	40	
Total other payables	24,287	30,362	21,99
Total other current liabilities	20,902	11,618	15,69
Total current liabilities	62,974	61,639	45,02
Non-current liabilities			
Total deferred tax liabilities	360	796	ı
Total other non-current liabilities	1,729	1,737	3,00
Total non-current liabilities	2,089	2,533	3,00
Total liabilities	65,063	64,172	48,02
Share capital			
Ordinary share	1,117,150	1,115,990	1,110,14
Advance receipts for share capital	1,983	2,211	1,09
Total share capital	1,119,133	1,118,201	1,111,23
Capital surplus			
Total capital surplus, additional paid-in capital	616,540	614,631	603,81
Capital surplus, treasury share transactions	2,812	2,812	2,81
Capital surplus, employee share options	3,613	3,876	8,74
Total capital surplus	622,965	621,319	615,37
Retained earnings	,	,	·
Total unappropriated retained earnings (accumulated deficit)	-257,595	-197,695	-125,00
Total retained earnings	-257,595	-197,695	-125,00
Other equity interest		,	,
Total other equity, others	0	n	
Total other equity interest	1 0	n	
Treasury shares	-87,611	-87,611	
Total equity	1,396,892	1,454,214	1,601,60
Total liabilities and equity	1,461,955	1,518,386	1,649,63
Number of share capital awaiting retirement	1,401,900	1,010,000	1,048,03
Equivalent issue shares of advance receipts for ordinary share	103,000	116,000	58,50
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	30,30

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Unit. N 1 \$ thousand				
Accounting Title	2016/01/01To2016/03/31	2015/01/01To2015/03/31		
Income Statement				
Total operating revenue	9,969	11,985		
Total operating costs	30,657	15,793		
Gross profit (loss) from operations	-20,688	-3,808		
Gross profit (loss) from operations	-20,688	-3,808		
Operating expenses				
Total selling expenses	2,085	587		
Total administrative expenses	7,078	6,618		
Total research and development expenses	41,076	32,430		
Total operating expenses	50,239	39,635		
Net operating income (loss)	-70,927	-43,443		
Non-operating income and expenses				
Total other income	13,371	10,772		
Other gains and losses, net	-2,279	-4,310		
Total non-operating income and expenses	11,092	6,462		
Profit (loss) from continuing operations before tax	-59,835	-36,981		
Total tax expense (income)	65	87		
Profit (loss) from continuing operations	-59,900	-37,068		
Profit (loss)	-59,900	-37,068		
Total comprehensive income	-59,900	-37,068		
Basic earnings per share				
Total basic earnings per share	-0.55	-0.33		

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/03/31	2015/01/01To2015/03/31
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-59,835	-36,981
Profit (loss) before tax	-59,835	-36,981
Depreciation expense	9,454	8,368
Amortization expense	212	345
Provision (reversal of provision) for bad debt expense	3	0.0
Interest income	-2,452	-5,026
Share-based payments	595	476
Impairment loss on non-financial assets	22	74
Other adjustments to reconcile profit (loss)	0	
Total adjustments to reconcile profit (loss)	7,834	4,237
Decrease (increase) in notes receivable due from related parties	7,004	4,237
Decrease (increase) in accounts receivable	12,992	29,629
Decrease (increase) in accounts receivable Decrease (increase) in accounts receivable due from related parties	-30	4,867
Decrease (increase) in accounts receivable due non related parties Decrease (increase) in other receivable	-9,654	-1,245
Decrease (increase) in other receivable Decrease (increase) in other receivable due from related parties	-9,004	-1,243
Decrease (increase) in other receivable due from related parties Decrease (increase) in inventories	-1,828	-3,677
Decrease (increase) in inventories Decrease (increase) in prepayments	-1,020	-5,677 454
Decrease (increase) in prepayments Decrease (increase) in other current assets	-708	-512
Total changes in operating assets	-11,414	29,516
Increase (decrease) in notes payable	4 024	1 100
Increase (decrease) in accounts payable	-1,834	-4,102
Increase (decrease) in accounts payable to related parties	-40	-23
Increase (decrease) in other payable	-10,917	-10,013
Increase (decrease) in other current liabilities	9,284	282
Increase (decrease) in net defined benefit liability	-8	40
Total changes in operating liabilities	-3,515	-13,816
Total changes in operating assets and liabilities	-14,929	15,700
Total adjustments	-7,095	19,937
Cash inflow (outflow) generated from operations	-66,930	-17,044
Income taxes refund (paid)	-174	-457
Net cash flows from (used in) operating activities	-67,104	-17,501
Cash flows from (used in) investing activities	70,000	00.000
Acquisition of investments in debt instrument without active market	-72,668	-30,000
Proceeds from disposal of investments in debt instrument without active market	321,709	1,005,749
Acquisition of property, plant and equipment	-21,243	-25,539
Increase in refundable deposits	-171	-124
Acquisition of intangible assets	0	U
Increase in prepayments for business facilities	-12,737	-1,596
Interest received	2,618	5,397
Net cash flows from (used in) investing activities	217,508	953,887
Cash flows from (used in) financing activities	1000	
Exercise of employee share options	1,983	1,092
Net cash flows from (used in) financing activities	1,983	1,092
Effect of exchange rate changes on cash and cash equivalents	0	C
Net increase (decrease) in cash and cash equivalents	152,387	937,478
Cash and cash equivalents at beginning of period	305,619	
Cash and cash equivalents at end of period	458,006	
Cash and cash equivalents reported in the statement of financial position	458,006	1,176,332
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Financial Statement - Statements of Changes in Stockholders' Equity

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

2016/03/31 Statement of Stockholders' Equity

Shire 141 y triousaria							2010/03/31 Statement of Stockholders Equity									
									Unit: NT\$ thousand							
Accounting Title	Ordinary share Advance re	receipts for share capital To	otal share capital Ca	pital surplus Unappr	opriated retained earnings (accumulated deficit) To	otal retained earnings	ngs Exchange differences on translation of foreign financial statements Gains (losses) from investn	estments in equity instruments measured at fair value through other comprehensive income Unrealized gain	ains (losses) on available-for-sale financial assets Gains (losses	s) on effective portion of cash flow hedges Gains (losses) on ef	ffective portion of hedges of net investments in foreign operations Change in fair value of financial liab	oility attributable to change in credit risk of liability Gains (losses) on reme	easurements of defined benefit Revaluatio	n surplus Equity related to non-current assets classified as held for sale	Others Total other equity into	erest Treasury shares Total equity
Equity at beginning of period	1,115,990	2,211	1,118,201	621,319	-197,695	-197,695	695	0	0	0	o	0	0	0	0	0 -87,611 1,454,214
Equity at beginning of period after adjustm	ments 1,115,990	2,211	1,118,201	621,319	-197,695	-197,695	695	0	0	0	0	0	0	0	0	0 -87,611 1,454,214
Profit (loss)	0	0	0	0	-59,900	-59,900	900	0	0	0	0	0	0	0	0	0 -59,900
Other comprehensive income	0	0	0	0	0	(0	0	0	0	o	0	0	0	0	0 0 0
Total comprehensive income	0	0	0	0	-59,900	-59,900	900	0	0	0	o	0	0	0	0	0 -59,900
Share-based payments	1,160	-228	932	1,646	0	(0	0	0	0	0	0	0	0	0	0 0 2,578
Total increase (decrease) in equity	1,160	-228	932	1,646	-59,900	-59,900	900	0	0	0	0	0	0	0	0	0 0 -57,322
Equity at end of period	1,117,150	1,983	1,119,133	622,965	-257,595	-257,595	595 0	0	0	0	0	0	0	0	0	0 -87,611 1,396,892
								20	015/03/31 Statement of Stockholders' Unit: NT\$ thousand	Equity						_
									Unit: NT\$ thousand							

						2013/03/31 Statement of						
						Unit: NT\$ tho	usand					
Accounting Title	Ordinary share Advance receipts for share cap	ital Total share capital	al Capital surplus	s Unappropriated retained earnings (accumulated defic	cit) Total retained earnings Exchange diffe	erences on translation of foreign financial statements Gains (losses) from investments in equity instruments mea	asured at fair value through other comprehensive income Unrealized gains (losses) on a	available-for-sale financial assets Gains (losses) on effective portion of cash flow hedge	Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-current	assets classified as held for sale Others Total othe	er equity interest Treasury s'	shares Total equit
Equity at beginning of period Effects of retrospective application and retrospective restatement	1,109,260 1,	660 1,110,920	0 614,121	-87,9	-87,935	0	0	0	0	0 0	0	1,637,10
Effects of retrospective application and retrospective restatement	0	0 0	0 0	0	0 0	0	0	0	0	0 0	0	- /
Retrospective adjustment of equity attributable to former owner due to reorganization of entities under common control	0	0 0	0 0		0 0	0	0	0	0	0 0	0	
Equity at beginning of period after adjustments	1,109,260 1,	660 1,110,920	0 614,121	-87,9	-87,935	0	0	0	0	0 0	0	1,637,10
Profit (loss)	0	0 0	0 0	-37,0	-37,068	0	0	0	0	0 0	0	-37,06′
Other comprehensive income	0	0 0	0 0	0	0 0	0	0	0	0	0 0	0	- /
Total comprehensive income	0	0 0	0 0	-37,0	-37,068	0	0	0	0	0 0	0	-37,06
Other comprehensive income Total comprehensive income Share-based payments Total increase (decrease) in equity Equity at end of period	885 -	568 317	7 1,251	1	0 0	0	0	0	0	0 0	0	1,56
Total increase (decrease) in equity	885 -	568 317	7 1,251	-37,0	-37,068	0	0	0	0	0 0	0	-35,50
Equity at end of period	1,110,145	092 1,111,237	7 615,372	-125,0	-125,003	0	0	0	0	0 0	0	1,601,60